orbofiban has been researched along with Coronary Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 11 (91.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fitzgerald, A; Fitzgerald, DJ; Muckian, C; O'Byrne, A; O'Neill, A; Shields, DC | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; de Lemos, JA; Gibson, CM; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS | 1 |
| Bentley, J; Blatt, A; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Cotter, G; Kaluski, E; Krakover, R; Lewis, B; Marmor, A; McCabe, CH; Michowitz, Y; Milo, O; Reisin, L; Vered, Z; Zimlichman, R | 1 |
| Ayanian, S; Braunwald, E; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Rifai, N; Sabatine, MS | 1 |
| Atar, S; Birnbaum, Y; Cannon, CP; Murphy, SA; Rosanio, S; Uretsky, BF | 1 |
| Braunwald, E; Cannon, CP; de Lemos, JA; McCabe, CH; Morrow, DA; Murphy, S; Rifai, N; Sabatine, MS; Scirica, BM; Wiviott, SD | 1 |
| Ferguson, JJ | 1 |
| Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG | 1 |
| Jang, IK; Sabatine, MS | 1 |
| Bhatt, DL; Chew, DP | 1 |
| Bhatt, DL; Chew, DP; Sapp, S; Topol, EJ | 1 |
| Byrne, CE; Cannon, CP; Fitzgerald, AP; Fitzgerald, DJ; Kenny, D; Moran, B; Muckian, C; O'Neill, PA; Shields, DC | 1 |
3 review(s) available for orbofiban and Coronary Disease
| Article | Year |
|---|---|
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Oral glycoprotein IIb/IIIa antagonists in coronary artery disease.
Topics: Administration, Oral; Alanine; Benzamidines; Coronary Disease; Humans; Integrins; Oximes; Piperidines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Oximes; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
6 trial(s) available for orbofiban and Coronary Disease
| Article | Year |
|---|---|
Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease.
Topics: Alanine; Alleles; Angina, Unstable; Collagen; Collagen Type III; Coronary Disease; Cross-Sectional Studies; Extracellular Matrix; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hemorrhage; Heterozygote; Humans; Minisatellite Repeats; Myocardial Infarction; Myocardial Ischemia; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines; Treatment Outcome | 2002 |
Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Alanine; Biomarkers; Chemokine CCL2; Cohort Studies; Confounding Factors, Epidemiologic; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Pyrrolidines; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Risk Factors; Survival Analysis; Time; Treatment Outcome | 2003 |
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysi
Topics: Aged; Alanine; Aspirin; Cerebrovascular Disorders; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Multivariate Analysis; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Pyrrolidines; Regression Analysis; Risk Factors; Treatment Outcome | 2003 |
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Recurrence; Risk; Syndrome | 2007 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heparin; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Stroke; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Topics: Alanine; Coronary Disease; Genotype; Glycoproteins; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Stroke; Thrombosis; Treatment Outcome | 2002 |
3 other study(ies) available for orbofiban and Coronary Disease
| Article | Year |
|---|---|
Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes.
Topics: Acute Disease; Alanine; Biomarkers; Coronary Disease; Female; Humans; Immunoassay; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Syndrome; Troponin I | 2003 |
Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Topics: Acute Disease; Administration, Oral; Aged; Alanine; Anticoagulants; Aspirin; Coronary Disease; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Patient Discharge; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Retrospective Studies; Risk Assessment; Severity of Illness Index; Syndrome | 2006 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Benzamidines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Disease; Dalteparin; Defibrillators, Implantable; Double-Blind Method; Enalapril; Endothelial Growth Factors; Fatty Acids, Omega-3; Guanidines; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Laser Therapy; Lymphokines; Metoprolol; Multicenter Studies as Topic; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pyrrolidines; Randomized Controlled Trials as Topic; Simvastatin; Sodium-Hydrogen Exchangers; Stents; Sulfones; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vitamin E | 1999 |